戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 r a mood disorder who had moderate or severe tardive dyskinesia.
2 lerability of valbenazine as a treatment for tardive dyskinesia.
3 idence rates of long-term treatment-emergent tardive dyskinesia.
4 horea associated with Huntington disease and tardive dyskinesia.
5 cern about long-term adverse effects such as tardive dyskinesia.
6  (VMAT2) inhibitor approved for treatment of tardive dyskinesia.
7  Symptom Rating Scale scores and no cases of tardive dyskinesia.
8  be examined for extrapyramidal symptoms and tardive dyskinesia.
9 term effects of valbenazine in patients with tardive dyskinesia.
10 ) receptor polymorphism on susceptibility to tardive dyskinesia.
11 mented the efficacy of vitamin E in treating tardive dyskinesia.
12 or efficacy of vitamin E in the treatment of tardive dyskinesia.
13 its inferences about adverse effects such as tardive dyskinesia.
14  response rate, extrapyramidal symptoms, and tardive dyskinesia.
15 linical symptoms, and occurrence of incident tardive dyskinesia.
16 tus has been implicated as a risk factor for tardive dyskinesia.
17 as Parkinson disease, Alzheimer disease, and tardive dyskinesia.
18  in AIMS scores for patients with refractory tardive dyskinesia.
19 al examination is required to identify early tardive dyskinesia.
20 s had at least moderate unawareness of their tardive dyskinesia.
21 4% versus 53%) and significantly less severe tardive dyskinesia.
22 otentially contribute to the pathogenesis of tardive dyskinesia.
23 , conceptual disorganization, akathisia, and tardive dyskinesia.
24 authors studied the use of tetrabenazine for tardive dyskinesia.
25  patients with schizophrenia, 11 of whom had tardive dyskinesia.
26 ine transporter-2 inhibitor-in patients with tardive dyskinesia.
27 ch may be relevant to the pathophysiology of tardive dyskinesia.
28    They examined the cumulative incidence of tardive dyskinesia 1, 3, 6, 9, and 12 months after the i
29 e a greater cumulative 12-month incidence of tardive dyskinesia (36.9%).
30  extrapyramidal side effects, akathisia, and tardive dyskinesia; 7) cataracts; and 8) myocarditis.
31 e found to be beneficial in the treatment of tardive dyskinesia, although this finding was not confir
32 uthors' goal was to compare the incidence of tardive dyskinesia among patients receiving olanzapine a
33 ence in the 12-month cumulative incidence of tardive dyskinesia among patients who had been neurolept
34  cumulative incidence of persistent emergent tardive dyskinesia among the 255 patients without dyskin
35      Patients assigned to clozapine had less tardive dyskinesia and fewer extrapyramidal side effects
36  which participates in antipsychotic-induced tardive dyskinesia and in levodopa-induced dyskinesia.
37 ditional targets are considered for treating tardive dyskinesia and negative and cognitive symptoms.
38 tardive dyskinesia or for the persistence of tardive dyskinesia and the associated structural changes
39 ls ineligible owing to treatment resistance, tardive dyskinesia, and history of suicide attempts.
40 t disorders, including Huntington's disease, tardive dyskinesia, and Tourette's syndrome.
41 f abuse, depression, Alzheimer's disease and tardive dyskinesias, and mediates subsequent long-term n
42 role of HP metabolites in the development of tardive dyskinesia are discussed.
43 including weight gain and the possibility of tardive dyskinesia, are reviewed.
44 arkinson's disease, Huntington's chorea, and tardive dyskinesia arise from an imbalance between these
45              The incidence of newly emergent tardive dyskinesia at any visit after baseline, at the f
46 ys of exposure) who did not have evidence of tardive dyskinesia at baseline.
47 tress and glutamatergic neurotransmission in tardive dyskinesia, both of which may be relevant to the
48 ation antipsychotics have a reduced risk for tardive dyskinesia, compared to first-generation antipsy
49  short mean durations and use of nonstandard tardive dyskinesia definitions.
50 of protein-oxidized products associated with tardive dyskinesia did not pass Bonferroni correction, h
51 ic dysfunction, extrapyramidal symptoms, and tardive dyskinesia), especially with long-term use.
52 rences, 2% and 22%), and higher incidence of tardive dyskinesia for chlorpromazine versus clozapine (
53              The authors studied the risk of tardive dyskinesia for older patients in the early stage
54        The weighted mean annual incidence of tardive dyskinesia for second-generation antipsychotics
55               Patients aged 18-80 years with tardive dyskinesia (>/=3 months before screening) were r
56 analysis (P<.001) and with lower symptoms of tardive dyskinesia in a secondary analysis including onl
57 horea associated with Huntington disease and tardive dyskinesia in adults.
58         The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients
59  were to investigate the rate (incidence) of tardive dyskinesia in elderly patients beginning treatme
60 anched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was
61                                  The risk of tardive dyskinesia in older outpatients is high, even wi
62 nce-daily valbenazine significantly improved tardive dyskinesia in participants with underlying schiz
63 fficacy and tolerability in the treatment of tardive dyskinesia in phase 2 studies.
64  to identify risk factors for development of tardive dyskinesia in this age group.
65 yramidal symptoms and having a lower risk of tardive dyskinesia in vulnerable clinical populations at
66                    Stratified by age, annual tardive dyskinesia incidence rates were 0.35% with secon
67 ed for 463 925 person-years), the annualized tardive dyskinesia incidence was 3.9% for second-generat
68                                              Tardive dyskinesia incidence was higher with second-gene
69                         Lack of awareness of tardive dyskinesia is a common feature in schizophrenia
70                                              Tardive dyskinesia is a movement disorder affecting 20%-
71                                              Tardive dyskinesia is a persistent movement disorder ind
72                                              Tardive dyskinesia is a serious and common complication
73                         Twenty patients with tardive dyskinesia (mean duration = 43.7 months) were vi
74  measure was a frequency count of videotaped tardive dyskinesia movements.
75 g > or =1 year and reporting on new cases of tardive dyskinesia or dyskinesia were systematically rev
76 thesis cannot account for the time course of tardive dyskinesia or for the persistence of tardive dys
77  Forty-three patients with schizophrenia and tardive dyskinesia participated in the study.
78                                              Tardive dyskinesia patients had significantly higher con
79 8, age 41.2 years, 71.2% male, 62.0% white), tardive dyskinesia prevalence rates were 13.1% for secon
80                               Differences in tardive dyskinesia rates between diagnostic groups found
81                                              Tardive dyskinesia rates for patients beginning treatmen
82                      To provide an update on tardive dyskinesia rates in patients treated with first-
83                                              Tardive dyskinesia results from exposure to dopamine rec
84            Current evidence supports a lower tardive dyskinesia risk for second-generation antipsycho
85 e correlations observed between decreases in tardive dyskinesia symptoms and decreases in aromatic am
86                                              Tardive dyskinesia symptoms correlated positively with m
87 ived placebo (N=18) in the percent change in tardive dyskinesia symptoms from baseline to the end of
88                             The reduction in tardive dyskinesia symptoms in the amino acids group was
89                 Patients were also rated for tardive dyskinesia symptoms with the Abnormal Involuntar
90  the >/=30% and >/=60% levels of decrease in tardive dyskinesia symptoms.
91                                              Tardive Dyskinesia (TD) can occur in people exposed to d
92                                              Tardive dyskinesia (TD) has no well-accepted treatments
93 VCMs) in rats is similar in many respects to tardive dyskinesia (TD) in humans.
94 induced by chronic haloperidol as a model of tardive dyskinesia (TD) in rats, we confirmed the antidy
95            There is controversy over whether tardive dyskinesia (TD) is solely a consequence of antip
96 extrapyramidal side effects (EPS), including tardive dyskinesia (TD).
97 zine therapeutic effects in the treatment of tardive dyskinesia (TD).
98 not induce extrapyramidal symptoms (EPS) and tardive dyskinesias (TDs).
99 on antipsychotics are expected to cause less tardive dyskinesia than first-generation antipsychotics.
100 showed significantly less awareness of their tardive dyskinesia than patients without the deficit syn
101 e (N = 87), the mean cumulative incidence of tardive dyskinesia was 3.4% and 5.9% at 1 and 3 months,
102                            A greater risk of tardive dyskinesia was associated with history of ECT tr
103                          Persistent emergent tardive dyskinesia was defined according to scores on th
104                                 Awareness of tardive dyskinesia was only modestly related to two of t
105                         Lack of awareness of tardive dyskinesia was stable over time.
106                      The cumulative rates of tardive dyskinesia were 25%, 34%, and 53% after 1, 2, an
107                                Patients with tardive dyskinesia were prohibited from assignment to pe
108 hotic treatment and presumably long-standing tardive dyskinesia were randomly assigned to receive bra
109 t Scale and research diagnostic criteria for tardive dyskinesia were used to define the comparative i
110 aspartate in their CSF than patients without tardive dyskinesia when age and neuroleptic dose were co
111        One hundred fifty-eight subjects with tardive dyskinesia who were receiving neuroleptic medica
112 tential for significant side effects such as tardive dyskinesia with long-term therapy, levodopa/carb
113 e potential of a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol
114  group, the observed incidence of persistent tardive dyskinesia with risperidone seemed to be much lo
115 acids constitute a novel, safe treatment for tardive dyskinesia, with a strong potential for providin
116 6 mg/day provided a significant reduction in tardive dyskinesia, with favourable safety and tolerabil

 
Page Top